Molecular structure of troglitazone
Find information on thousands of medical conditions and prescription drugs.

Troglitazone

Troglitazone (Rezulin®, Resulin® or Romozin®) is a member of the drug class of the thiazolidinediones. It was introduced in the late 1990s but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. It was withdrawn from the USA market on 21 March 2000, and from other markets soon afterwards. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
Oxytetracycline
Phentermine
Tacrine
Tacrolimus
Tagamet
Talbutal
Talohexal
Talwin
Tambocor
Tamiflu
Tamoxifen
Tamsulosin
Tao
Tarka
Taurine
Taxol
Taxotere
Tazarotene
Tazobactam
Tazorac
Tegretol
Teicoplanin
Telmisartan
Temazepam
Temocillin
Temodar
Temodar
Temozolomide
Tenex
Teniposide
Tenoretic
Tenormin
Tenuate
Terazosin
Terbinafine
Terbutaline
Terconazole
Terfenadine
Teriparatide
Terlipressin
Tessalon
Testosterone
Tetrabenazine
Tetracaine
Tetracycline
Tetramethrin
Thalidomide
Theo-24
Theobid
Theochron
Theoclear
Theolair
Theophyl
Theophyl
Theostat 80
Theovent
Thiamine
Thiomersal
Thiopental sodium
Thioridazine
Thorazine
Thyroglobulin
Tiagabine
Tianeptine
Tiazac
Ticarcillin
Ticlopidine
Tikosyn
Tiletamine
Timolol
Timoptic
Tinidazole
Tioconazole
Tirapazamine
Tizanidine
TobraDex
Tobramycin
Tofranil
Tolazamide
Tolazoline
Tolbutamide
Tolcapone
Tolnaftate
Tolterodine
Tomoxetine
Topamax
Topicort
Topiramate
Tora
Toradol
Toremifene
Tracleer
Tramadol
Trandate
Tranexamic acid
Tranxene
Tranylcypromine
Trastuzumab
Trazodone
Trenbolone
Trental
Trest
Tretinoin
Triacetin
Triad
Triamcinolone
Triamcinolone hexacetonide
Triamterene
Triazolam
Triclabendazole
Triclosan
Tricor
Trifluoperazine
Trilafon
Trileptal
Trimetazidine
Trimethoprim
Trimipramine
Trimox
Triprolidine
Triptorelin
Tritec
Trizivir
Troglitazone
Tromantadine
Trovafloxacin
Tubocurarine chloride
Tussionex
Tylenol
Tyrosine
U
V
W
X
Y
Z

Troglitazone, like the other thiazolidinediones (pioglitazone and rosiglitazone), works by activating PPARs (peroxisome proliferator-activated receptors). Troglitazone is a ligand to both PPARα and - more strongly - PPARγ. Troglitazone also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity in addition to its PPAR activation. It has been shown (Aljada et al) to reduce inflammation: troglitazone use was associated with a decrease of nuclear factor kappa-B (NFκB) and a concomitant increase in its inhibitor (IκB). NFκB is an important cellular transcription regulator for the immune response.

Read more at Wikipedia.org


[List your site here Free!]


Troglitazone—Primary Prevention For Type 2 Diabetes? - Brief Article - Statistical Data Included
From Nutrition Research Newsletter, 1/1/00 by J. Frias

Troglitazone has been found effective in improving glycemic control in type 2 diabetics. It appears to enhance peripheral insulin sensitivity in diabetics as well as in obese, nondiabetic individuals. It is thought to possibly improve B-cell function in those with impaired glucose tolerance as well, implying that it may play a role as a primary prevention method of type 2 diabetes.

University of California researchers attempted to further investigate the metabolic effects of troglitazone in type 2 diabetics, as well as obese and lean individuals, in a recent study. They also evaluated the metabolic effects of troglitazone two to three weeks following discontinuation of this medication in diabetic subjects.

Nine type 2 diabetics, nine obese individuals (BMI [is greater than] 26 kg/[m.sup.2], and nine lean subjects were studied. The subjects participated in baseline metabolic studies consisting of an eight-hour meal tolerance test and a five-hour glucose clamp. Following completion of the baseline studies, subjects began taking 600 mg of troglitazone per day. Diabetic subjects had stopped taking all oral hypoglycemic agents two to three weeks prior to baseline. Subjects remained on the treatment for 12 weeks. At the completion of the 12-week period, repeat metabolic studies were performed. Diabetic subjects remained off of oral hypoglycemic agents and were given another five-hour glucose clamp study after two to three weeks.

Results show a significant decrease in fasting plasma glucose and a significant enhancement of insulin-stimulated glucose disposal during treatment in the diabetic subjects. A positive correlation between the change in fasting hepatic glucose output (HGO) and the change in fasting plasma glucose with troglitazone in the diabetic subjects was seen. When all therapy was discontinued for two to three weeks, neither plasma glucose nor insulin-stimulated glucose disposal showed significant change. In the obese subjects, researchers saw an improvement in insulin-stimulated glucose disposal when taking troglitazone. This resulted in maintenance of euglycemia through the lowering of plasma insulin concentrations. There was an observed increase in both glucose clearance and fasting HGO in lean subjects.

This study shows that troglitazone lowers fasting and postprandial glucose in type 2 diabetics by improving peripheral insulin sensitivity and through affecting hepatic glucose output. It appears to have insulin-sensitizing effects in obese individuals. This suggests that troglitazone may potentially be used for the primary prevention of type 2 diabetes.

J. Frias, Y. Druszynska, J. Yu, et al., Metabolic Effects of Troglitazone Therapy in Type 2 Diabetic, Obese, and Lean Normal Subjects, Diabetes Care 23:64-69 (January 2000) [Correspondence: Jerrold M. Olefsky, MD, Division of Endocrinology and Metabolism, University of California at San Diego, La Jolla, CA 92093. E-mail: jolefsky@uscd.edu.]

COPYRIGHT 2000 Technical Insights, a divison of John Wiley & Sons.
COPYRIGHT 2000 Gale Group

Return to Troglitazone
Home Contact Resources Exchange Links ebay